Goldman Sachs Remains a Buy on Eli Lilly (LLY) With an $883 Price Target

Eli Lilly and Company (NYSE:LLY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider from Goldman Sachs maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) on June 11, keeping the price target at $883.00 and supporting the rating with several operational and strategic factors that lend LLY a favorable market position.

The analyst reasoned that Eli Lilly and Company (NYSE:LLY) has exhibited strong demand trends, especially in the incretin class. This coincides with its 2025 guidance and suggests solid growth potential. Management is also actively focusing on drug pricing negotiations with the administration and is undertaking efforts to bring out-of-pocket costs down for consumers.

Eli Lilly and Company’s (NYSE:LLY) business development strategy is another factor supporting the analyst’s positive rating, as it focuses on expansion in core therapeutic areas, emphasizing smaller, earlier-stage deals without disregarding larger opportunities. This strategic focus aligns with the company’s focus on growth and innovation, as does its interest in the PD1/L1xVEGF bispecific space.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.